Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 58

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 58
---
 until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates.

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.

<div align='center'>S-2</div>

The Offering

| Common Stock Offered by Us                         |     | Shares of our common stock having an aggregate offering price of up to $200,000,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Common Stock to be Outstanding After This Offering |     | Up to 226,821,098 shares, assuming sales of 46,511,627 shares of our common stock in this offering at an offering price of $4.30 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on November 4, 2025. The actual number of shares of common stock issued will vary depending on the sales price under this offering.                                                                                                                                                                                                                                      |
| Manner of Offering                                 |     | “At the market offering” that may be made from time to time on The Nasdaq Global Market or such other national securities exchange on which our common stock is then listed, through our sales agent, Jefferies. See the section entitled “Plan of Distribution” on pageS-11of this prospectus.                                                                                                                                                                                                                                                                                                             |
| Use of Proceeds                                    |     | Our management will retain broad discretion regarding the allocation and use of any net proceeds. We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, primarily to fund research and development and clinical